Zentalis Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ZNTL | PAR.AX | ZBIO | ZYME | ALXO | BBOT | |
|---|---|---|---|---|---|---|
| Market cap | 172.69M | 153.48M | 1.85B | 2.22B | 188.06M | 184.40M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.0 | 1.3 | -6.1 | 25.5 | -2.5 | -0.8 |
| Price/book | 0.9 | 40.8 | 7.3 | 27.5 | 1.4 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +32.84% | −36.36% | −7.04% | +72.85% | +15.25% | −81.29% |
| Today | −1.12% | 0.00% | +0.28% | +2.69% | +5.43% | −0.86% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ZNTL news ›Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
The Manila Times SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azeno
Zevra Therapeutics, Inc. $ZVRA Stock: Profund Advisors LLC Grows Holdings
Posted by Mitch Edgeman on Nov 3rd, 2026 Get Our Latest Report on ZVRA Shares of ZVRA stock opened at $10.10 on Tuesday. Zevra Therapeutics, Inc. has a 1-year low of $8.01 and a 1-year high of $15.03. The company has a market…
Ermenegildo Zegna (NYSE:ZGN) Stock Rated Moderate Buy in New Coverage at Royal Bank Of Canada
Posted by Danessa Lincoln on Oct 28th, 2026 Stock analysts at Royal Bank Of Canada began coverage on shares of Ermenegildo Zegna (NYSE:ZGN – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat…
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
Posted by Sarita Garza on Oct 27th, 2026 Adam Schayowitz, Zymeworks’ head of R&D, said Roche is expected to fund research and development for ZW209, including the Phase 1a study, while Zymeworks will conduct the initial global trial. Roche…
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
Objective Response Rate (ORR) and Duration of Response (DOR): The updated ORR includes a patient with a confirmed response after the prior cutoff. The current median DOR of 5.5 months reflects a more mature dataset with less censoring than…
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
The published abstract reports results for OS, a secondary endpoint of DENALI Part 1b in patients with platinum-resistant ovarian cancer (PROC), from an interim analysis. As of the September 2, 2025 data cutoff: The abstract is available…
Zentalis Pharmaceuticals (ZNTL) Gets a Hold from Wells Fargo
Wells Fargo analyst Yanan Zhu maintained a Hold rating on Zentalis Pharmaceuticals yesterday and set a price target of $5.00. The company’s shares closed yesterday at $2.72. According to TipRanks, Zhu is a 5-star analyst with an average…
Zai Lab (NASDAQ: ZLAB) agrees to $250 million private placement financing
Posted by Defense World Staff on Oct 25th, 2026 Zai Lab Limited (NASDAQ: ZLAB) entered a securities purchase agreement for 11,340,000 American Depositary Shares in a private placement financing. Each ADS represents ten ordinary shares, and…
More from 1 other outlet
Zentalis announces first OS data from DENALI part 1b study
Zentalis (ZNTL) Pharmaceuticals announced that overall survival, OS, data from an interim analysis of the DENALI Part 1b study, GOG-3066, have b... Zentalis announces first OS data from DENALI part 1b study Zentalis (ZNTL) Pharmaceuticals…
From the 4Search news index, newest first.